Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC)

Vincent Lam, Søren M. Bentzen, Pranshu Mohindra, Elizabeth M. Nichols, Neha Bhooshan, Melissa Vyfhuis, Katherine A. Scilla, Steven J. Feigenberg, Martin J. Edelman, Josephine Feliciano

Research output: Contribution to journalArticle

Abstract

Objectives To determine the prognostic effect of Body Mass Index (BMI) in definitively treated locally advanced NSCLC patients. Materials and methods In this single institution retrospective cohort study, we evaluated 291 patients who were treated for locally advanced NSCLC from 2000 to 2010. They were stratified into four BMI groups based on World Health Organization criteria: underweight (<18.5 kg/m2), normal weight (18.5 to <25 kg/m2), overweight (25 to <30 kg/m2), and obese (≧30 kg/m2). Overall survival was analyzed by BMI group. Results Baseline patient characteristics and treatment parameters were similar between obese and normal weight patients. Increasing BMI was associated with improved overall survival (P = 0.011), even when underweight cases were excluded. There was a sustained 31%–58% reduction in mortality of obese relative to normal weight patients (HR 0.68 ± 0.21, 0.61 ± 0.19, and 0.42 ± 0.19, for each year post-treatment respectively). Statin use after diagnosis was highly associated with increasing BMI (P < 0.001) and predicted improved survival in a multivariate analysis (HR 0.60, 95% CI 0.41–0.89, P = 0.011). Conclusion Obese patients in this retrospective study had significantly improved survival relative to normal weight patients. Our data suggest that the protective effect of obesity in locally advanced NSCLC is not solely due to short-term treatment effects, decreased smoking exposure, or poor prognostic factors from underweight patients. Notably, statin use was also associated with improved survival. Additional studies are needed to clarify the mechanisms and possible concomitant factors underlying the obesity paradox in NSCLC.

Original languageEnglish (US)
Pages (from-to)52-57
Number of pages6
JournalLung Cancer
Volume104
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Obesity
Survival
Body Mass Index
Thinness
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Weights and Measures
Retrospective Studies
Cohort Studies
Therapeutics
Multivariate Analysis
Smoking
Mortality

Keywords

  • BMI (Body Mass Index)
  • Locally advanced
  • Lung cancer
  • Non-small cell
  • Obesity
  • Statin

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). / Lam, Vincent; Bentzen, Søren M.; Mohindra, Pranshu; Nichols, Elizabeth M.; Bhooshan, Neha; Vyfhuis, Melissa; Scilla, Katherine A.; Feigenberg, Steven J.; Edelman, Martin J.; Feliciano, Josephine.

In: Lung Cancer, Vol. 104, 01.02.2017, p. 52-57.

Research output: Contribution to journalArticle

Lam, V, Bentzen, SM, Mohindra, P, Nichols, EM, Bhooshan, N, Vyfhuis, M, Scilla, KA, Feigenberg, SJ, Edelman, MJ & Feliciano, J 2017, 'Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC)', Lung Cancer, vol. 104, pp. 52-57. https://doi.org/10.1016/j.lungcan.2016.11.017
Lam, Vincent ; Bentzen, Søren M. ; Mohindra, Pranshu ; Nichols, Elizabeth M. ; Bhooshan, Neha ; Vyfhuis, Melissa ; Scilla, Katherine A. ; Feigenberg, Steven J. ; Edelman, Martin J. ; Feliciano, Josephine. / Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). In: Lung Cancer. 2017 ; Vol. 104. pp. 52-57.
@article{0d4b94b966a64a49bfa1b91598743336,
title = "Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC)",
abstract = "Objectives To determine the prognostic effect of Body Mass Index (BMI) in definitively treated locally advanced NSCLC patients. Materials and methods In this single institution retrospective cohort study, we evaluated 291 patients who were treated for locally advanced NSCLC from 2000 to 2010. They were stratified into four BMI groups based on World Health Organization criteria: underweight (<18.5 kg/m2), normal weight (18.5 to <25 kg/m2), overweight (25 to <30 kg/m2), and obese (≧30 kg/m2). Overall survival was analyzed by BMI group. Results Baseline patient characteristics and treatment parameters were similar between obese and normal weight patients. Increasing BMI was associated with improved overall survival (P = 0.011), even when underweight cases were excluded. There was a sustained 31{\%}–58{\%} reduction in mortality of obese relative to normal weight patients (HR 0.68 ± 0.21, 0.61 ± 0.19, and 0.42 ± 0.19, for each year post-treatment respectively). Statin use after diagnosis was highly associated with increasing BMI (P < 0.001) and predicted improved survival in a multivariate analysis (HR 0.60, 95{\%} CI 0.41–0.89, P = 0.011). Conclusion Obese patients in this retrospective study had significantly improved survival relative to normal weight patients. Our data suggest that the protective effect of obesity in locally advanced NSCLC is not solely due to short-term treatment effects, decreased smoking exposure, or poor prognostic factors from underweight patients. Notably, statin use was also associated with improved survival. Additional studies are needed to clarify the mechanisms and possible concomitant factors underlying the obesity paradox in NSCLC.",
keywords = "BMI (Body Mass Index), Locally advanced, Lung cancer, Non-small cell, Obesity, Statin",
author = "Vincent Lam and Bentzen, {S{\o}ren M.} and Pranshu Mohindra and Nichols, {Elizabeth M.} and Neha Bhooshan and Melissa Vyfhuis and Scilla, {Katherine A.} and Feigenberg, {Steven J.} and Edelman, {Martin J.} and Josephine Feliciano",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.lungcan.2016.11.017",
language = "English (US)",
volume = "104",
pages = "52--57",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC)

AU - Lam, Vincent

AU - Bentzen, Søren M.

AU - Mohindra, Pranshu

AU - Nichols, Elizabeth M.

AU - Bhooshan, Neha

AU - Vyfhuis, Melissa

AU - Scilla, Katherine A.

AU - Feigenberg, Steven J.

AU - Edelman, Martin J.

AU - Feliciano, Josephine

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Objectives To determine the prognostic effect of Body Mass Index (BMI) in definitively treated locally advanced NSCLC patients. Materials and methods In this single institution retrospective cohort study, we evaluated 291 patients who were treated for locally advanced NSCLC from 2000 to 2010. They were stratified into four BMI groups based on World Health Organization criteria: underweight (<18.5 kg/m2), normal weight (18.5 to <25 kg/m2), overweight (25 to <30 kg/m2), and obese (≧30 kg/m2). Overall survival was analyzed by BMI group. Results Baseline patient characteristics and treatment parameters were similar between obese and normal weight patients. Increasing BMI was associated with improved overall survival (P = 0.011), even when underweight cases were excluded. There was a sustained 31%–58% reduction in mortality of obese relative to normal weight patients (HR 0.68 ± 0.21, 0.61 ± 0.19, and 0.42 ± 0.19, for each year post-treatment respectively). Statin use after diagnosis was highly associated with increasing BMI (P < 0.001) and predicted improved survival in a multivariate analysis (HR 0.60, 95% CI 0.41–0.89, P = 0.011). Conclusion Obese patients in this retrospective study had significantly improved survival relative to normal weight patients. Our data suggest that the protective effect of obesity in locally advanced NSCLC is not solely due to short-term treatment effects, decreased smoking exposure, or poor prognostic factors from underweight patients. Notably, statin use was also associated with improved survival. Additional studies are needed to clarify the mechanisms and possible concomitant factors underlying the obesity paradox in NSCLC.

AB - Objectives To determine the prognostic effect of Body Mass Index (BMI) in definitively treated locally advanced NSCLC patients. Materials and methods In this single institution retrospective cohort study, we evaluated 291 patients who were treated for locally advanced NSCLC from 2000 to 2010. They were stratified into four BMI groups based on World Health Organization criteria: underweight (<18.5 kg/m2), normal weight (18.5 to <25 kg/m2), overweight (25 to <30 kg/m2), and obese (≧30 kg/m2). Overall survival was analyzed by BMI group. Results Baseline patient characteristics and treatment parameters were similar between obese and normal weight patients. Increasing BMI was associated with improved overall survival (P = 0.011), even when underweight cases were excluded. There was a sustained 31%–58% reduction in mortality of obese relative to normal weight patients (HR 0.68 ± 0.21, 0.61 ± 0.19, and 0.42 ± 0.19, for each year post-treatment respectively). Statin use after diagnosis was highly associated with increasing BMI (P < 0.001) and predicted improved survival in a multivariate analysis (HR 0.60, 95% CI 0.41–0.89, P = 0.011). Conclusion Obese patients in this retrospective study had significantly improved survival relative to normal weight patients. Our data suggest that the protective effect of obesity in locally advanced NSCLC is not solely due to short-term treatment effects, decreased smoking exposure, or poor prognostic factors from underweight patients. Notably, statin use was also associated with improved survival. Additional studies are needed to clarify the mechanisms and possible concomitant factors underlying the obesity paradox in NSCLC.

KW - BMI (Body Mass Index)

KW - Locally advanced

KW - Lung cancer

KW - Non-small cell

KW - Obesity

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=85007271419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007271419&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2016.11.017

DO - 10.1016/j.lungcan.2016.11.017

M3 - Article

C2 - 28213000

AN - SCOPUS:85007271419

VL - 104

SP - 52

EP - 57

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -